by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
News Bulletin : ADA News Bulletin May 2011
Did you know that up to of smokers would try and quit on their dentists' advice?1 38% In fact dental professionals are now recognised as having a significant role to play in smoking prevention; however, advising patients on quitting smoking may not be a routine part of clinical practice for many.2 As such Pfizer has developed a specific dental smoking cessation information pack to assist dentists in offering simple advice to their patients who smoke and a referral to their general practitioner for smoking cessation treatments if appropriate. CHAMPIX® (varenicline as tartrate) is a prescription-only, oral smoking cessation treatment from Pfizer.3 It is a non-nicotine treatment that acts in two ways;1 1) it partially stimulates the nicotine receptors in the brain, releasing a small amount of dopamine to alleviate the symptoms of craving and withdrawal,3--6 and 2) it simultaneously blocks the same nicotine receptors preventing the rewarding and reinforcing effects of smoking.3,4,6 A clinical study has shown that CHAMPIX® increases the odds of quitting at 1 year by almost 3-fold versus placebo alone (p<0001).7 Furthermore, when quitting with CHAMPIX®, patients report less cravings and urge to smoke, as well as less satisfaction and reward from smoking versus placebo,4,8 --11 or NRT patches.12 In addition, nicotine withdrawal symptoms can also be relieved with CHAMPIX® therapy. 3--5 The good news is that the Government subsidises a full 12-week course of CHAMPIX®, as well as an additional 12 weeks of CHAMPIX® for patients who are abstinent at the end of the initial 12 weeks of therapy13 to further increase their chances of success.14 You can help Dental Patients Quit Cases of neuropsychiatric symptoms such as depressed mood, agitation, aggression, hallucinations, anxiety, psychosis, mood swings, changes in behaviour or thinking, suicidal ideation and suicide have been reported during post-marketing experience with CHAMPIX®. The role of CHAMPIX® in these reports is not known. Patients on CHAMPIX® should be observed for neuropsychiatric symptoms and worsening of pre-existing psychiatric illness. Patients and their families should be advised to stop CHAMPIX® and see their doctor at the first sign of any of these symptoms. Ongoing follow-up should be provided until these symptoms resolve. BEFORE PRESCRIBING, PLEASE REVIEW FULL PRODUCT INFORMATION AVAILABLE FROM PFIZER AUSTRALIA PTY LTD. CHAMPIX® (varenicline as tartrate) 0.5mg and 1mg Tablets. INDICATIONS: Aid to smoking cessation in adults (≥18 years). CONTRAINDICATIONS: Hypersensitivity to varenicline or excipients. PRECAUTIONS: Neuropsychiatric symptoms : history of or underlying psychiatric illness; serious symptoms including changes in behaviour or thinking, anxiety, psychosis, mood swings, agitation, hallucinations, aggression, depressed mood, suicidal ideation and suicidal behaviour; patients and families to monitor; patients to stop taking CHAMPIX® at fir st sign of symptoms and contact a health care professional immediately; ongoing follow-up until resolution. Not studied in serious psychiatric illness (schizophrenia, bipolar disorder, major depressive disorder) or epilepsy. Post-marketing reports of rare but potentially fatal hyper sensitivity reactions including angioedema, Stevens-Johnson Syndrome, Erythema Multiforme. Theophylline, warfarin, insulin, CYP1A2 substrates, nicotine replacement therapy. Driving or operating machinery. Pregnancy, lactation. See full PI for details. ADVERSE EFFECTS: Smoking cessation/nicotine withdrawal symptoms. Most common: nausea, insomnia, abnormal dreams, headache, constipation, flatulence, dry mouth, dysgeusia, dizziness. Post-marketing reports of myocardial infarction* and stroke*. See full PI for details. DOSAGE AND ADMINISTRATION: Patients should set a date to quit smoking. Dosing should start 1--2 weeks before this date. Days 1--3: 0.5mg once daily. Days 4--7: 0.5mg twice daily. Day 8--end of 12 week treatment: 1mg twice daily. Pos sible additional 12 week PBS Information: This product is authority listed on the PBS as an aid for smoking cessation for adults. Refer to PBS schedule for full information. ADVERTORIAL
ADA News Bulletin April 2011
ADA News Bulletin June 2011